IRIDEX CORP - 10-Q Summary (Quarter Ended April 2, 2011)
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for IRIDEX Corporation, a provider of therapeutic laser systems for ophthalmology and aesthetics. The report covers the three-month period ended April 2, 2011. The company operates in two segments: Ophthalmology and Aesthetics, selling products domestically and internationally through a direct sales force and distributors.
Key Financial Metrics
| Metric | Q1 2011 | Q1 2010 |
|---|---|---|
| Total Revenues | $11.2 million | $10.8 million |
| Gross Profit | $5.2 million | $5.2 million |
| Gross Margin | 46.7% | 48.6% |
| Net Income | $0.6 million | $0.5 million |
| Diluted EPS | $0.06 | $0.05 |
| Cash and Equivalents | $8.6 million | $6.4 million |
| Working Capital | $17.7 million | $17.2 million |
| Operating Cash Flow | ($0.2 million) | $0.6 million |
| Debt | $0 (No borrowings outstanding) | $0 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 3.7% year-over-year. Ophthalmology revenue grew 7.9% (driven by a 54.5% increase in domestic system sales and 5.0% growth in recurring consumable sales), while Aesthetics revenue declined 6.3% due to economic uncertainty and competition.
- Margin Compression: Gross margin decreased 1.9 percentage points to 46.7%. Management attributed this to manufacturing variances (an expense of 1.1% of revenue vs. a credit of 1.3% in the prior year) and a 1.2% decrease in direct margins due to product mix.
- Cash Flow: Operating cash flow turned negative ($0.2 million outflow) compared to a $0.6 million inflow in the prior year, primarily due to increases in accounts receivable and payments for accrued compensation.
- Stock Repurchases: The company repurchased 75,698 shares of common stock for $0.3 million in a private transaction with American Medical Systems Holdings, Inc.
Outlook, Risks, and Management Commentary
- Subsequent Event: On May 5, 2011, the Board approved a new $2.0 million stock repurchase program.
- Liquidity: Management believes current cash ($8.6 million) and operating cash flows are sufficient for the next 12 months. A $5.0 million revolving credit facility with Silicon Valley Bank is available but currently unused.
- Risks: Key risks include reliance on international sales (44.7% of total), competition in the aesthetics market, potential delays in new product introductions, and the expiration of the "Connector Patent" in 2010 which may increase competition for consumable devices.
- Tax Position: The company has a deferred tax asset of approximately $12.1 million fully offset by a valuation allowance. The effective tax rate for the quarter was 14.49%.
Investor Verification Checklist
- Verify the sustainability of the 54.5% growth in domestic ophthalmology system sales.
- Monitor the trend in Aesthetics revenue, which continues to face headwinds from the economic environment.
- Assess the impact of the expired "Connector Patent" on recurring consumable revenue and market share.
- Review the utilization of the new $2.0 million stock repurchase program.
- Confirm the company's ability to maintain positive operating cash flow given the recent quarterly outflow.